期刊
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
卷 9, 期 3, 页码 376-391出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X16630712
关键词
bile acids; drug therapy; liver disease; nonalcoholic fatty liver disease; primary biliary cholangitis; primary sclerosing cholangitis
资金
- National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC)
- MRC [MR/L001489/1] Funding Source: UKRI
Recent developments in understanding the role of bile acids (BAs) as signalling molecules in human metabolism and inflammation have opened new avenues in the field of hepatology research. BAs are no longer considered as simple molecules helping in fat digestion but as agents with real therapeutic value in treating complex autoimmune and metabolic liver diseases. BAs and their receptors such as farnesoid X receptor, transmembrane G protein-coupled receptor 5 and peroxisome proliferator-activated receptor have been identified as novel targets for drug development. Some of these novel pharmaceuticals are already in clinical evaluation with the most advanced drugs having reached phase III trials. Chronic liver diseases such as primary biliary cholangitis, primary sclerosing cholangitis and nonalcoholic fatty liver disease, for which there is no or limited pharmacotherapy, are most likely to gain from these developments. In this review we discuss recent and the most relevant basic and clinical research findings related to BAs and their implications for novel therapy for chronic liver diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据